Diabetes Drug
Beyond insulin, where is the innovation?
A (Endocrinologist): GLP-1 agonists (Ozempic, Mounjaro) have changed everything. They lower A1c and cause weight loss. But supply and cost are crises.
B (Pharmacist): Don’t forget SGLT2 inhibitors. They protect kidneys and hearts, even in non-diabetics with CKD. That’s a massive label expansion.
C (Payer): We can’t afford $1,000/month per patient. We are forcing step therapy (metformin first). Drug companies need to compete on price.
D (Patient): I was on metformin for 10 years with GI side effects. These new drugs gave me my life back. Stop gatekeeping based on cost.
12 Views
Hi @Pratiksha Dhote,
It's refreshing to hear your perspectives on the ongoing innovations in diabetes management. The advancements with GLP-1 agonists and SGLT2 inhibitors truly mark a significant leap forward in treatment options, showcasing not just how far we've come, but also the path ahead with challenges like affordability.
Prioritizing patients health and access while also encouraging pharmaceutical companies to offer competitive pricing is essential as this will create a balanced approach. As we navigate these complexities, it’s vital to integrate patient experiences like the one shared. After all, at the heart of healthcare innovation is the goal to enhance lives. Let's keep pushing for solutions that make these breakthroughs accessible for all!